Despite the shortness of the therapeutic intervention, treatment delayed the occurrence of lethal AML (Figure 3b) and led to a shift in the composition of engrafted human leukocytes from CD33+ AML blasts to CD3+ T cells in the bone marrow (Figure 3c). This evidence concerns the gene CD33 and acute myeloid leukemia.